A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours

J. L. Pico, G. Rosti, A. Kramar, H. Wandt, V. Koza, R. Salvioni, C. Theodore, G. Lelli, W. Siegert, A. Horwich, M. Marangolo, W. Linkesch, G. Pizzocaro, H. J. Schmoll, J. Bouzy, J. P. Droz, P. Biron

Research output: Contribution to journalArticle

189 Citations (Scopus)

Abstract

Background: Incomplete remission or relapse from first-line chemotherapy has poor prognosis in male germ cell tumour patients. This phase III randomised trial compares conventional salvage to high-dose-intensification chemotherapy. Patients and methods: Between February 1994 and September 2001, 280 patients from 43 institutions in 11 countries, were randomly assigned to receive either four cycles of cisplatin, ifosfamide and etoposide (or vinblastine) (arm A), or three such cycles followed by high-dose carboplatin, etoposide and cyclophosphamide (CarboPEC) with haematopoietic stem cell support (arm B). Results: Similar complete and partial response rates were observed in both treatment arms (56%; 95% CI 50% to 62%). There were 3% and 7% toxic deaths in arms A and B, respectively. No significant improvements with CarboPEC were observed in either 3-year event-free survival (35% versus 42%, P=0.16) or overall survival (53%; 95% CI 46% to 59%). Complete responders with CarboPEC had a significant improvement in disease-free survival (55% versus 75% at 3 years, P

Original languageEnglish
Pages (from-to)1152-1159
Number of pages8
JournalAnnals of Oncology
Volume16
Issue number7
DOIs
Publication statusPublished - Jul 2005

Fingerprint

Salvage Therapy
Germ Cell and Embryonal Neoplasms
Etoposide
Platinum
Carboplatin
Cyclophosphamide
Drug Therapy
Disease-Free Survival
Ifosfamide
Vinblastine
Poisons
Hematopoietic Stem Cells
Cisplatin
Recurrence
Survival
Therapeutics

Keywords

  • CarboPEC
  • Germ cell tumours
  • High-dose chemotherapy
  • Randomised trial

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. / Pico, J. L.; Rosti, G.; Kramar, A.; Wandt, H.; Koza, V.; Salvioni, R.; Theodore, C.; Lelli, G.; Siegert, W.; Horwich, A.; Marangolo, M.; Linkesch, W.; Pizzocaro, G.; Schmoll, H. J.; Bouzy, J.; Droz, J. P.; Biron, P.

In: Annals of Oncology, Vol. 16, No. 7, 07.2005, p. 1152-1159.

Research output: Contribution to journalArticle

Pico, JL, Rosti, G, Kramar, A, Wandt, H, Koza, V, Salvioni, R, Theodore, C, Lelli, G, Siegert, W, Horwich, A, Marangolo, M, Linkesch, W, Pizzocaro, G, Schmoll, HJ, Bouzy, J, Droz, JP & Biron, P 2005, 'A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours', Annals of Oncology, vol. 16, no. 7, pp. 1152-1159. https://doi.org/10.1093/annonc/mdi228
Pico, J. L. ; Rosti, G. ; Kramar, A. ; Wandt, H. ; Koza, V. ; Salvioni, R. ; Theodore, C. ; Lelli, G. ; Siegert, W. ; Horwich, A. ; Marangolo, M. ; Linkesch, W. ; Pizzocaro, G. ; Schmoll, H. J. ; Bouzy, J. ; Droz, J. P. ; Biron, P. / A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. In: Annals of Oncology. 2005 ; Vol. 16, No. 7. pp. 1152-1159.
@article{30df6451dff643b4b037d890861965c7,
title = "A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours",
abstract = "Background: Incomplete remission or relapse from first-line chemotherapy has poor prognosis in male germ cell tumour patients. This phase III randomised trial compares conventional salvage to high-dose-intensification chemotherapy. Patients and methods: Between February 1994 and September 2001, 280 patients from 43 institutions in 11 countries, were randomly assigned to receive either four cycles of cisplatin, ifosfamide and etoposide (or vinblastine) (arm A), or three such cycles followed by high-dose carboplatin, etoposide and cyclophosphamide (CarboPEC) with haematopoietic stem cell support (arm B). Results: Similar complete and partial response rates were observed in both treatment arms (56{\%}; 95{\%} CI 50{\%} to 62{\%}). There were 3{\%} and 7{\%} toxic deaths in arms A and B, respectively. No significant improvements with CarboPEC were observed in either 3-year event-free survival (35{\%} versus 42{\%}, P=0.16) or overall survival (53{\%}; 95{\%} CI 46{\%} to 59{\%}). Complete responders with CarboPEC had a significant improvement in disease-free survival (55{\%} versus 75{\%} at 3 years, P",
keywords = "CarboPEC, Germ cell tumours, High-dose chemotherapy, Randomised trial",
author = "Pico, {J. L.} and G. Rosti and A. Kramar and H. Wandt and V. Koza and R. Salvioni and C. Theodore and G. Lelli and W. Siegert and A. Horwich and M. Marangolo and W. Linkesch and G. Pizzocaro and Schmoll, {H. J.} and J. Bouzy and Droz, {J. P.} and P. Biron",
year = "2005",
month = "7",
doi = "10.1093/annonc/mdi228",
language = "English",
volume = "16",
pages = "1152--1159",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "7",

}

TY - JOUR

T1 - A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours

AU - Pico, J. L.

AU - Rosti, G.

AU - Kramar, A.

AU - Wandt, H.

AU - Koza, V.

AU - Salvioni, R.

AU - Theodore, C.

AU - Lelli, G.

AU - Siegert, W.

AU - Horwich, A.

AU - Marangolo, M.

AU - Linkesch, W.

AU - Pizzocaro, G.

AU - Schmoll, H. J.

AU - Bouzy, J.

AU - Droz, J. P.

AU - Biron, P.

PY - 2005/7

Y1 - 2005/7

N2 - Background: Incomplete remission or relapse from first-line chemotherapy has poor prognosis in male germ cell tumour patients. This phase III randomised trial compares conventional salvage to high-dose-intensification chemotherapy. Patients and methods: Between February 1994 and September 2001, 280 patients from 43 institutions in 11 countries, were randomly assigned to receive either four cycles of cisplatin, ifosfamide and etoposide (or vinblastine) (arm A), or three such cycles followed by high-dose carboplatin, etoposide and cyclophosphamide (CarboPEC) with haematopoietic stem cell support (arm B). Results: Similar complete and partial response rates were observed in both treatment arms (56%; 95% CI 50% to 62%). There were 3% and 7% toxic deaths in arms A and B, respectively. No significant improvements with CarboPEC were observed in either 3-year event-free survival (35% versus 42%, P=0.16) or overall survival (53%; 95% CI 46% to 59%). Complete responders with CarboPEC had a significant improvement in disease-free survival (55% versus 75% at 3 years, P

AB - Background: Incomplete remission or relapse from first-line chemotherapy has poor prognosis in male germ cell tumour patients. This phase III randomised trial compares conventional salvage to high-dose-intensification chemotherapy. Patients and methods: Between February 1994 and September 2001, 280 patients from 43 institutions in 11 countries, were randomly assigned to receive either four cycles of cisplatin, ifosfamide and etoposide (or vinblastine) (arm A), or three such cycles followed by high-dose carboplatin, etoposide and cyclophosphamide (CarboPEC) with haematopoietic stem cell support (arm B). Results: Similar complete and partial response rates were observed in both treatment arms (56%; 95% CI 50% to 62%). There were 3% and 7% toxic deaths in arms A and B, respectively. No significant improvements with CarboPEC were observed in either 3-year event-free survival (35% versus 42%, P=0.16) or overall survival (53%; 95% CI 46% to 59%). Complete responders with CarboPEC had a significant improvement in disease-free survival (55% versus 75% at 3 years, P

KW - CarboPEC

KW - Germ cell tumours

KW - High-dose chemotherapy

KW - Randomised trial

UR - http://www.scopus.com/inward/record.url?scp=25144455744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25144455744&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdi228

DO - 10.1093/annonc/mdi228

M3 - Article

VL - 16

SP - 1152

EP - 1159

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 7

ER -